Robotic Bronchoscopy Market (2026-2036)
The global robotic bronchoscopy market is projected to reach USD 4.20 billion by 2036 from an estimated USD 1.05 billion in 2026, at a CAGR of 14.8% during the forecast period from 2026 to 2036.
- Published
- Jul 2026
- Pages
- 316
- Format
- PDF + Excel
- Report ID
- MR-2101
- Base year
- 2025
- 2026 · ESTIMATED
- $1.05B
- 2036
- $4.20B
- CAGR 2026–2036
- 14.8%
2025 baseline · 2026–2036 forecast at 14.8% CAGR · hover a bar for the value
Key highlights
The global robotic bronchoscopy market is projected to reach USD 4.20 billion by 2036, growing at a CAGR of 14.8% during 2026 to 2036.
Rising global lung cancer incidence and the expansion of low-dose CT screening programs are driving a steady increase in the number of indeterminate lung nodules that require biopsy.
Robotic platforms are displacing conventional and CT-guided transthoracic approaches by offering higher diagnostic yield with a meaningfully lower risk of pneumothorax.
Hospitals are increasingly combining diagnosis, lymph node staging, and therapeutic intervention into a single anesthetic event, shortening the patient's path from detection to treatment.
The robotic systems segment holds the largest revenue share in 2026, while catheters and consumables are expected to grow the fastest given the shift toward single-use, disposable bronchoscopes.
Shape-sensing navigation is the fastest-growing navigation technology, while electromagnetic navigation retains the broadest installed base in 2026.
The peripheral lung nodule biopsy application holds the largest share in 2026, while therapeutic interventions, including ablation, are expected to grow the fastest.
The hospitals segment holds the largest share in 2026, while specialty and comprehensive cancer centers are expected to register the fastest growth.
North America accounts for the largest share of the global market in 2026, supported by early clinical adoption and a deep base of platform manufacturers.
Asia-Pacific is expected to witness the fastest growth over the forecast period, driven by rising lung cancer burden and the emergence of domestic robotic platforms in China.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026 to 2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 14.8% |
| Format | PDF, Excel & Cloud Portal · 316 pages |
| Market Size (Value) in 2026 | USD 1.05 Billion |
| Market Size (Value) in 2036 | USD 4.20 Billion |
| Segments Covered | By Component - Robotic Systems, Catheters & Consumables, Software & Navigation Platforms, Services By Navigation Technology - Electromagnetic Navigation, Shape-Sensing (Fiber-Optic) Navigation, Vision-Based Navigation By Application - Peripheral Lung Nodule Biopsy, Lymph Node Staging, Therapeutic Interventions (Ablation, Fiducial Marker Placement) By End User - Hospitals, Ambulatory Surgical Centers, Specialty & Comprehensive Cancer Centers, Academic & Research Institutes |
| Countries Covered | North America (U.S., Canada), Europe (Germany, U.K., France, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, South Korea, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa) |
| Key Companies | Intuitive Surgical, Inc. (U.S.), Johnson & Johnson MedTech (Auris Health, Inc.) (U.S.), Medtronic plc (Ireland), Noah Medical Corporation (U.S.), Shanghai MicroPort MedBot (Group) Co., Ltd. (China), Broncus Holding Corporation (China), Body Vision Medical Ltd. (Israel), Olympus Corporation (Japan), and LungCare Medical Technologies Co., Ltd. (China). |
Report overview
Segments covered: component, navigation technology, application, end user. Regions: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
Robotic bronchoscopy is a minimally invasive technology that uses a robotically controlled catheter to navigate deep into the branching airways of the lung, enabling physicians to access small peripheral pulmonary nodules with greater stability and precision than conventional flexible bronchoscopy. Before the procedure, physicians use three-dimensional reconstructions of computed tomography (CT) images to plan the navigation pathway. During the procedure, the robotic catheter is advanced through the bronchial tree using a handheld or console-based controller. Once the target lesion is reached, biopsy instruments including needles, forceps, or brushes are introduced through the working channel to obtain tissue samples. Many centers supplement navigation with cone-beam CT, digital tomosynthesis, or fluoroscopy to compensate for CT-to-body divergence and confirm accurate lesion localization.
The clinical value of robotic bronchoscopy lies in its ability to improve access to peripheral lung lesions while reducing procedural challenges associated with traditional diagnostic techniques. Although CT-guided transthoracic needle biopsy provides high diagnostic accuracy, it carries a pneumothorax risk that may exceed 20–25% in some patient populations and does not permit simultaneous mediastinal lymph node staging. Robotic bronchoscopy offers stable catheter control, enhanced maneuverability in distal airways, and the ability to combine peripheral lung biopsy with endobronchial ultrasound-guided lymph node staging during the same procedure, potentially improving procedural efficiency while maintaining a favorable safety profile.
Since the introduction of the first commercial robotic bronchoscopy platform in 2018, adoption has expanded steadily across academic medical centers and tertiary hospitals, with subsequent launches of both electromagnetic navigation- and shape-sensing-based systems. Clinical evidence has demonstrated high navigation success, favorable diagnostic yield for peripheral pulmonary nodules, and low complication rates, supporting broader adoption beyond early-adopter institutions. Continued growth in lung cancer screening programs, increasing detection of small pulmonary nodules, and expanding evidence supporting image-guided diagnostic and therapeutic bronchoscopy are expected to accelerate adoption across community hospitals and comprehensive cancer centers.
Report infographic
Market dynamics
5 factors across 2 forcesRising Global Lung Cancer Burden and Expansion of Low-Dose CT Screening
Lung cancer remains the leading cause of cancer death worldwide, and a large share of the disease is still caught late, when treatment options narrow sharply. That is starting to change as low-dose CT screening programs expand across high-risk populations in North America, Europe, and parts of Asia. Screening finds nodules, and most of those nodules sit in the lung's peripheral, harder-to-reach airways, which is exactly the terrain robotic bronchoscopy was built to navigate. As more health systems roll out or expand screening eligibility, the pipeline of nodules requiring a definitive tissue diagnosis keeps growing, and each one is a potential robotic bronchoscopy candidate.
Superior Diagnostic Yield and Safety Profile Relative to Conventional Biopsy Routes
Robotic platforms have built a substantial clinical evidence base showing diagnostic yields that consistently outperform earlier-generation electromagnetic navigation and manual bronchoscopy, while avoiding the higher pneumothorax risk associated with CT-guided transthoracic needle biopsy. Hospitals adopting these platforms have reported the share of lung cancers caught at an early, more treatable stage rising substantially within a few years of adoption. As more peer-reviewed outcomes data accumulates and gets published in respected clinical journals, referring physicians and tumor boards are increasingly steering appropriate patients toward robotic bronchoscopy as the first-line diagnostic route rather than a fallback option.
Shift Toward Combined Diagnosis, Staging, and Therapy in a Single Anesthetic Event
A growing number of centers are pairing robotic bronchoscopy with endobronchial ultrasound for lymph node staging, and in some cases with ablation or fiducial marker placement, all within one anesthesia event. This "single anesthetic pathway" cuts the number of procedures a patient undergoes, shortens the time from suspicious finding to treatment, and has been shown in published cost analyses to meaningfully lower total episode cost by avoiding repeat sedation and separate staging procedures. For hospitals under pressure to improve throughput and patient experience, this consolidated workflow is becoming a strong argument for capital investment in robotic platforms.
Table of contents
12 chapters · 120 sections · 316 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Component | Robotic Systems | Catheters and consumables |
| By Navigation Technology | Electromagnetic navigation | Shape-Sensing Navigation |
| By Application | Peripheral Lung Nodule Biopsy | — |
| By End User | Hospitals | Specialty and comprehensive cancer centers |
By Component
- Robotic Systems Lead the Market in 2026
- Robotic systems account for the largest share of revenue in 2026, reflecting the significant upfront capital investment hospitals make to acquire a platform.
- Catheters and consumables are expected to register the fastest growth over the forecast period, driven by the shift toward single-use, disposable bronchoscopes designed to reduce cross-contamination risk and simplify sterile processing, alongside the recurring, procedure-linked revenue this consumables model generates for manufacturers.
By Navigation Technology
- Electromagnetic Navigation Leads, Shape-Sensing Navigation Grows Fastest
- Electromagnetic navigation holds the broadest installed base in 2026, reflecting its longer commercial history and integration across multiple platforms.
- Shape-sensing navigation, which measures the catheter's shape hundreds of times per second without relying on external electromagnetic fields, is expected to grow the fastest as it gains adoption for its precision advantages in reaching very small, deep peripheral nodules.
By Application
- Peripheral lung nodule biopsy remains the core, largest-share application in 2026, as it is the primary reason hospitals invest in these platforms.
- Therapeutic interventions, including tumor ablation and fiducial marker placement, are expected to grow the fastest as manufacturers extend their catheter platforms beyond pure diagnostics.
By End User
- Hospitals Lead the Market in 2026
- Hospitals hold the largest share in 2026, given the capital intensity of platform acquisition and the need for integrated anesthesia, radiology, and thoracic surgery support.
- Specialty and comprehensive cancer centers are expected to grow the fastest as dedicated lung cancer programs increasingly build robotic bronchoscopy into their standard diagnostic pathway.
Geographic analysis
North America
Largest shareNorth America holds the largest share of the global robotic bronchoscopy market in 2026, anchored by the United States, where the leading platforms first launched and where clinical evidence, reimbursement pathways, and hospital familiarity are most mature. North America Leads the Market in 2026
Asia-Pacific
Fastest growthAsia-Pacific is expected to record the fastest growth over the forecast period, supported by rising lung cancer incidence, expanding screening infrastructure, and the emergence of domestically developed and regulatory-approved robotic platforms in China.
Europe
Europe remains an important market, with adoption growing steadily as clinical societies incorporate robotic bronchoscopy into interventional pulmonology guidance.
Competitive landscape
- In March 2025
, Johnson & Johnson MedTech received FDA clearance for Monarch Quest, a software platform that enhances the Monarch robotic bronchoscopy system by integrating advanced navigation, intraprocedural three-dimensional imaging, and AI-powered navigation running on an NVIDIA accelerated computing platform, significantly increasing real-time computational performance.
- In October 2025
, Noah Medical presented clinical results at the CHEST 2025 Annual Meeting demonstrating 97% tool-in-lesion confirmation using its TiLT+ imaging technology, 96.7% concordance with cone-beam CT confirmation, and a 96.7% overall diagnostic yield under predefined study criteria.
- In December 2025
, Shanghai MicroPort MedBot received National Medical Products Administration (NMPA) approval for its UniPath Electronic Bronchoscopic Surgical Robotic System, designed to support the diagnosis and treatment of peripheral pulmonary lesions through an ultra-slim robotic catheter capable of navigating complex bronchial pathways.
- In Q1 2026
, Intuitive Surgical reported 39% year-over-year growth in Ion robotic bronchoscopy procedure volume and highlighted continued investments in expanding clinical indications, including lung staging, and integrating AI-enabled rapid on-site evaluation technologies.
- Intuitive Surgical, Inc. (U.S.)
- Medtronic plc · Ireland
- Noah Medical Corporation (U.S.)
- Shanghai MicroPort MedBot (Group) Co., Ltd. · China
- Broncus Holding Corporation · China
- Body Vision Medical Ltd. · Israel
- Olympus Corporation · Japan
- Ambu A/S · Denmark
Expert perspectives
“We are moving past the era where robotic bronchoscopy was seen as a tool for a handful of academic centers. Community hospitals are now asking how quickly they can get a platform installed and staff trained, because the diagnostic yield data has become difficult to ignore.”
“The next phase for this category is therapeutic. Diagnosis was the entry point, but the real opportunity is using the same catheter that found the nodule to treat it, whether that's ablation or fiducial placement for radiation therapy.”
“Cost of ownership is still the conversation every capital committee wants to have. The platforms that will win the next round of hospital adoption are the ones that can show a clear return through single-anesthesia workflows and reduced repeat procedures, not just better images.”
Frequently asked questions
The global robotic bronchoscopy market size is estimated at USD 1.05 billion in 2026.
Cite this report
Meticulous Research. (2026). Robotic Bronchoscopy Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2101). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/robotic-bronchoscopy-market-6784